The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Sickle Cell Disease Treatment Market Change Between 2026 And 2030?
The sickle cell disease treatment market has experienced rapid expansion in recent years. It is projected to increase from $3.51 billion in 2025 to $4.11 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.3%. The growth observed in the historic period can be attributed to factors such as the high prevalence of the disease in Africa and Americas, limited availability of treatments, a reliance on blood transfusions, the expansion of hematology research, and insufficient early diagnostic awareness.
The sickle cell disease treatment market size is anticipated to undergo significant expansion in the coming years, projected to reach $7.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 18.1%. This projected growth during the forecast period is attributable to several factors, including the emergence of gene therapy solutions, the increased availability of biologics and targeted drugs, the integration of predictive diagnostics, a rise in global healthcare initiatives, and the development of personalized treatment plans for patients. Key trends expected in this period encompass the development of gene-editing therapies, greater access to hydroxyurea, advancements in blood transfusion management, the adoption of advanced diagnostics for early detection, and the expansion of patient support and disease management programs.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13048&type=smp
Which Growth Factors Are Strengthening The Sickle Cell Disease Treatment Market Landscape?
The growing number of blood and bone marrow transplants is anticipated to fuel the expansion of sickle cell disease treatment in the coming period. A blood and bone marrow transplant is a medical process that substitutes unhealthy blood-forming cells with healthy ones. The aim of a bone marrow transplant is to treat sickle cell diseases and cancers by introducing healthy bone marrow cells into an individual after their diseased bone marrow has been processed to eliminate abnormal cells. These replacement cells can originate either from the patient’s own body (an autologous transplant) or from a donor’s body (an allogeneic transplant). For instance, in June 2024, data from the National Transplant Organization (ONT), an independent coordinating agency based in Spain, indicated that in 2023, Spain incorporated 23,686 donors into the Spanish Bone Marrow Donor Registry, an 8% increase from 2022, and performed a record 3,717 hematopoietic stem cell transplants, which corresponds to 77.4 transplants per million population. Consequently, the increasing prevalence of blood and bone marrow transplants will stimulate the sickle cell disease treatment market.
Which Segment Groups Define The Sickle Cell Disease Treatment Market Landscape?
The sickle cell disease treatment market covered in this report is segmented –
1) By Treatment Modality: Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant
2) By Disease Type: Sickle Cell Anemia, Hemoglobin Sickle C Disease (HbSC), Other Disease Types
3) By Route Of Administration: Oral, Parenteral
4) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Blood Transfusion: Regular Blood Transfusion, Exchange Transfusion
2) By Pharmacotherapy: Hydroxyurea, L-Glutamine, Voxelotor, Crizanlizumab
3) By Bone Marrow Transplant: Allogeneic Transplant, Autologous Transplant
What Trends Are Influencing The Sickle Cell Disease Treatment Market Outlook?
Leading companies within the short bowel syndrome market are concentrating on advancing medical science through innovations like treatments for intestinal failure, with the goal of offering improved therapeutic choices that enhance patient results for those with gastrointestinal disorders. Intestinal failure represents a severe condition where the small intestine is incapable of absorbing sufficient nutrients, fluids, and electrolytes necessary for proper hydration and nutrition. As an illustration, in May 2024, Ironwood Pharmaceuticals, Inc., a US-based healthcare entity, disclosed new data from studies examining apraglutide in adults diagnosed with short bowel syndrome and intestinal failure (SBS-IF). Apraglutide, functioning as a next-generation GLP-2 analog, exhibited potential in improving intestinal absorption and reducing the need for parenteral support. These findings underscore the drug’s effectiveness, safety, and enduring advantages, reflecting Ironwood’s dedication to creating innovative treatments for gastrointestinal conditions.
Who Are The Businesses Driving Activity In The Sickle Cell Disease Treatment Market?
Major companies operating in the sickle cell disease treatment market are Sun Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Medunik USA Inc., Zydus Cadila Healthcare Ltd., Graphite Bio Inc., Addmedica, Emmaus Medical Inc., Bluebird bio Inc., CRISPR Therapeutics AG, GlycoMimetics Inc., Mast Therapeutics Inc.
Access The Complete Sickle Cell Disease Treatment Market Report:
https://www.thebusinessresearchcompany.com/report/sickle-cell-disease-treatment-global-market-report
Which Region Has The Strongest Presence In The Sickle Cell Disease Treatment Market?
North America was the largest region in the sickle cell disease treatment market in 2025. The regions covered in the sickle cell disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Sickle Cell Disease Treatment Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=13048&type=smp
Browse Through More Reports Similar to the Global Sickle Cell Disease Treatment Market 2026, By The Business Research Company
Cells Therapy Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report
Rare Diseases Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report
Cell Therapy Technologies Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/cell-therapy-technologies-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model